[go: up one dir, main page]

CL2018001705A1 - Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. - Google Patents

Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.

Info

Publication number
CL2018001705A1
CL2018001705A1 CL2018001705A CL2018001705A CL2018001705A1 CL 2018001705 A1 CL2018001705 A1 CL 2018001705A1 CL 2018001705 A CL2018001705 A CL 2018001705A CL 2018001705 A CL2018001705 A CL 2018001705A CL 2018001705 A1 CL2018001705 A1 CL 2018001705A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
antioxidant
composition
amorphous lenalidomide
pharmaceutically acceptable
Prior art date
Application number
CL2018001705A
Other languages
English (en)
Inventor
Martinez Marta Vivancos
Fernandez Lisardo Alvarez
Calzada Jose Velada
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of CL2018001705A1 publication Critical patent/CL2018001705A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LENALIDOMIDA AMORFA, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, CON UN ANTIOXIDANTE SINTÉTICO Y UNO O MÁS EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES. LA INVENCIÓN SE RELACIONA ADEMÁS CON UN PROCESO DE FABRICACIÓN DE DICHA COMPOSICIÓN Y EL USO DE DICHA COMPOSICIÓN COMO MEDICAMENTO, ESPECIALMENTE EN EL TRATAMIENTO DE MIELOMA MÚLTIPLE Y SÍNDROMES MIELODIPLÁSICOS.
CL2018001705A 2015-12-22 2018-06-21 Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. CL2018001705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15202069 2015-12-22

Publications (1)

Publication Number Publication Date
CL2018001705A1 true CL2018001705A1 (es) 2018-08-10

Family

ID=55068830

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001705A CL2018001705A1 (es) 2015-12-22 2018-06-21 Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.

Country Status (7)

Country Link
US (2) US10328028B2 (es)
EP (1) EP3393457A1 (es)
AU (1) AU2016378482A1 (es)
CL (1) CL2018001705A1 (es)
EA (1) EA036205B1 (es)
MX (1) MX385876B (es)
WO (1) WO2017109041A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
PL3394033T3 (pl) 2015-12-22 2021-05-31 Incyte Corporation Związki heterocykliczne jako immunomodulatory
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018013693A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
JP2021500379A (ja) 2017-10-26 2021-01-07 シンバイアス ファーマ アー・ゲー レナリドミド即放性製剤
WO2019138424A1 (en) * 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
PL3774791T3 (pl) 2018-03-30 2023-06-05 Incyte Corporation Związki heterocykliczne jako immunomodulatory
WO2019199136A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
LT4219492T (lt) 2018-05-11 2025-03-10 Incyte Corporation Heterocikliniai junginiai kaip imunomoduliatoriai
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
CN114829366A (zh) 2019-11-11 2022-07-29 因赛特公司 Pd-1/pd-l1抑制剂的盐及结晶形式
CN110664761A (zh) * 2019-11-18 2020-01-10 杭州百诚医药科技股份有限公司 一种来那度胺药物组合物及其制备方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
JP2024503001A (ja) * 2021-01-08 2024-01-24 スタートン セラピューティクス インコーポレイテッド 非経口用の免疫調節イミド化合物の安定溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191566B1 (pl) 1996-07-24 2006-06-30 Celgene Corp Podstawiona 1-oksoizoindolina, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2011513497A (ja) 2008-03-11 2011-04-28 ドクター・レディーズ・ラボラトリーズ・リミテッド レナリドミドの調製
AU2009321374A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
JP5727944B2 (ja) * 2009-03-02 2015-06-03 ジェネリクス・［ユーケー］・リミテッド 改良プロセス
CN101537184B (zh) * 2009-04-30 2011-04-20 杭州中美华东制药有限公司 一种含水难溶高活性药物的组合物及其制备方法
CA2793312C (en) 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
US20150126582A1 (en) * 2012-04-30 2015-05-07 Sevion Therapeutics, Inc. Combination Treatment of Multiple Myeloma
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103705485B (zh) * 2013-12-31 2015-07-22 广州帝奇医药技术有限公司 一种用于治疗骨髓增生异常综合症的组合物及其制备方法

Also Published As

Publication number Publication date
US20180256501A1 (en) 2018-09-13
WO2017109041A1 (en) 2017-06-29
US20190240157A1 (en) 2019-08-08
US10328028B2 (en) 2019-06-25
MX385876B (es) 2025-03-18
US11007152B2 (en) 2021-05-18
EP3393457A1 (en) 2018-10-31
EA201891489A1 (ru) 2018-11-30
AU2016378482A1 (en) 2018-07-12
MX2018007704A (es) 2018-11-09
EA036205B1 (ru) 2020-10-14

Similar Documents

Publication Publication Date Title
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
GEP20217239B (en) Pharmaceutical composition
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2016002971A1 (es) Combinación.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
GT201700223A (es) Imidazopirazinonas como inhibidores de pde 1
CL2015002897A1 (es) Inhibidores de bace1
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CO2017002472A2 (es) Formulación de acetato de abiraterona
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
GEP20217240B (en) Pharmaceutical composition
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia